- Home
- DNUT vs BEAM Comparison
DNUT vs BEAM Comparison
Compare DNUT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNUT
- BEAM
- Stock Information
- Founded
- DNUT 1937
- BEAM 2017
- Country
- DNUT United States
- BEAM United States
- Employees
- DNUT N/A
- BEAM N/A
- Industry
- DNUT Food Chains
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNUT Consumer Staples
- BEAM Health Care
- Exchange
- DNUT Nasdaq
- BEAM Nasdaq
- Market Cap
- DNUT 505.6M
- BEAM 1.9B
- IPO Year
- DNUT 2021
- BEAM 2020
- Fundamental
- Price
- DNUT $3.08
- BEAM $19.45
- Analyst Decision
- DNUT Buy
- BEAM Strong Buy
- Analyst Count
- DNUT 8
- BEAM 11
- Target Price
- DNUT $9.73
- BEAM $48.90
- AVG Volume (30 Days)
- DNUT 4.0M
- BEAM 2.4M
- Earning Date
- DNUT 08-07-2025
- BEAM 08-05-2025
- Dividend Yield
- DNUT 4.54%
- BEAM N/A
- EPS Growth
- DNUT N/A
- BEAM N/A
- EPS
- DNUT N/A
- BEAM N/A
- Revenue
- DNUT $1,597,883,000.00
- BEAM $63,578,000.00
- Revenue This Year
- DNUT N/A
- BEAM N/A
- Revenue Next Year
- DNUT $2.37
- BEAM $17.18
- P/E Ratio
- DNUT N/A
- BEAM N/A
- Revenue Growth
- DNUT N/A
- BEAM N/A
- 52 Week Low
- DNUT $2.50
- BEAM $13.53
- 52 Week High
- DNUT $12.68
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- DNUT 49.49
- BEAM 63.94
- Support Level
- DNUT $3.22
- BEAM $20.75
- Resistance Level
- DNUT $3.47
- BEAM $22.51
- Average True Range (ATR)
- DNUT 0.20
- BEAM 1.18
- MACD
- DNUT 0.04
- BEAM 0.35
- Stochastic Oscillator
- DNUT 58.12
- BEAM 74.58
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.